中科信息(300678) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥87,187,750.46, representing a 16.97% increase compared to ¥74,535,937.15 in the same period last year[3] - Net profit attributable to shareholders decreased by 19.02% to ¥7,588,015.41 from ¥9,369,849.59 year-on-year[3] - Basic and diluted earnings per share fell by 45.99% to ¥0.0256 from ¥0.0474 in the same period last year[3] - Net profit for Q1 2024 was ¥6,822,509.44, a decrease of 16.5% from ¥8,166,481.07 in Q1 2023[20] - Total operating revenue for Q1 2024 reached ¥87,187,750.46, an increase of 16.5% compared to ¥74,535,937.15 in the same period last year[19] - Total operating costs amounted to ¥83,914,915.43, up from ¥72,377,873.78, reflecting a year-over-year increase of 16.0%[19] - The total comprehensive income for Q1 2024 was ¥6,822,509.44, down from ¥8,166,481.07 in the same period last year[21] Cash Flow and Assets - The net cash flow from operating activities improved by 22.79%, reaching -¥95,482,299.18 compared to -¥123,663,827.04 in the previous year[3] - Cash received from other operating activities increased by 137.80% to ¥6,718,382.41 compared to ¥2,825,200.43 in the same period last year[7] - The company's cash and cash equivalents decreased to RMB 355,578,148.71 from RMB 501,298,208.11, reflecting a decline of approximately 29%[15] - The total cash and cash equivalents at the end of the period amounted to CNY 346,259,422.11, up from CNY 286,252,306.42 year-over-year[24] - The company reported a total cash outflow of CNY 201,761,642.08 from operating activities, compared to CNY 223,256,415.05 in the previous year[24] Investments and Expenses - Research and development expenses increased by 46.96% to ¥8,435,218.78 from ¥5,739,796.03 year-on-year, indicating a significant investment in innovation[7] - Investment cash payments surged by 532.91% to ¥50,000,000.00 from ¥7,900,000.00, reflecting increased investment in financial assets[7] - Total cash outflow from investment activities was CNY 50,060,729.36, compared to CNY 8,041,955.28 in the same period last year[24] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 64,436, with the largest shareholder being the Chinese Academy of Sciences Holding Co., Ltd., holding 30.53% of shares[9] - Total equity attributable to shareholders reached ¥871,692,236.23, up from ¥864,104,220.82, reflecting a growth of 0.7%[20] Liabilities and Financial Position - Total liabilities as of Q1 2024 were ¥257,451,468.15, a decrease from ¥398,471,223.60 in the previous year[20] - Current liabilities decreased to RMB 252,816,561.64 from RMB 392,060,318.83, a reduction of about 35%[16] - The company reported a significant reduction in accounts payable, which decreased to RMB 116,259,690.86 from RMB 186,259,289.57, a drop of about 38%[16] Other Notable Points - The company has no new product launches or technological developments mentioned in the report[12] - There are no significant market expansion or acquisition strategies outlined in the current report[12] - The company did not undergo an audit for the first quarter report[25] - The company has not adopted the new accounting standards for the current year[25]